MedPath

Autologous Platelet Rich Plasma on Low Back Pain

Not Applicable
Conditions
Low Back Pain
Interventions
Other: PRP Treatment(P)
Drug: Medication Treatment(Loxoprofen Sodium tablets,M)
Registration Number
NCT02983747
Lead Sponsor
Shanghai Changzheng Hospital
Brief Summary

The purpose of this study is to evaluate the effectiveness of autologous platelet-rich plasma (PRP) injection therapy for low back pain patients. Our hypothesis is that PRP will reduce the pain feeling and benefit for restore of the intervertebral disk.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
112
Inclusion Criteria
  • Chronic low back pain more than 2months
  • Visual analog scale score more than 4
  • Positive X-ray, MRI or CT scan findings
  • Pfirrmann grading I-III
  • Well understanding and communication ability
Read More
Exclusion Criteria
  • History of allergy
  • Hemorrhagic trend or use of anticoagulant therapy
  • Mental diseases
  • Active infection or recent infectious diseases within 3 months
  • Local skin infection near the puncture location
  • Severe lumbar spinal stenosis, lumbar spondylolisthesis, ossification of posterior longitudinal
  • Ligament and lumbar disc herniation(more than 5mm)
  • Immunologic diseases
  • Tumors
  • Metastatic disease
  • Recent surgery less than 3 months)
  • Pregnancy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PRP Treatment(P)PRP Treatment(P)PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
PRP Treatment(P)Medication Treatment(Loxoprofen Sodium tablets,M)PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
Medication Treatment(M)Medication Treatment(Loxoprofen Sodium tablets,M)NSAIDs medication(Loxoprofen Sodium tablets) therapy only.
Primary Outcome Measures
NameTimeMethod
Visual Analog Scale(VAS)1 year

Pain relief evaluated using change from baseline in Visual Analog Scale (VAS):baseline, 1 week ,and 1 month, 2 months, 6 months, 12 months after intervention.

Secondary Outcome Measures
NameTimeMethod
Functional Rating Index1 year

Spinal functions evaluated using change from baseline by Functional Rating Index: baseline, 1 week ,and 1 month, 2 months, 6 months, 12 months after intervention.

Oswestry Disability Index (ODI)1 year

Pain relief and functions evaluated using change from baseline in Oswestry Disability Index (ODI): baseline, 1 week ,and 1 month, 2 months, 6 months, 12 months after intervention.

Measuring the Quality of life using SF-36 questionnaire1 year

Functions evaluated using change from baseline in SF-36:baseline, 1 week ,and 1 month, 2 months, 6 months, 12 months after intervention.

Imaging change1 year

Imaging change by MRI scan: : baseline, 1 month, 6 months, 12 months after intervention.

Number of patients with side effectWithin 1 year after injection therapy

Record how many patients had side effects after intervention (eg.aggravation of pain\*(VAS change increased more than 3 from baseline),anaphylaxis,sensory/motion disturbances).

Trial Locations

Locations (1)

Shanghai Changzheng Hospital

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath